Roche AmpliChip to Help Merck Investigate Role of p53 DNA Damage in Cancer Rx Response

Merck will use Roche's microarray-based AmpliChip p53 test in clinical studies to assess which cancer patients are likely to respond to drugs that are currently in development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.